NDA 021366 · Astrazeneca
Crestor
Rosuvastatin Calcium · Oral
NovelOrphanLast checked: Nov 20, 2026Latest source record: Sep 23, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2003
Aug 12, 2003
Approved uses
7
Original approval plus efficacy supplements
Registered trials
824
189 Phase 3, 59 recruiting
FAERS reports
207,891
140,698 serious, 12,446 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Sep 23, 2026.
CRESTOR is indicated: • To reduce the risk of major adverse cardiovascular (CV) events (CV death, nonfatal myocardial infarction, nonfatal stroke, or an arterial revascularization procedure) in adults at increased risk for these events. • As an adjunct to diet and exercise to reduce low-density lipoprotein cholesterol (LDL-C): ∘ in adults with hypercholesterolemia. ∘ and slow the progression of atherosclerosis in adults. ∘ in adults and pediatric patients aged 8 years and older with heterozygous familial hypercholesterolemia (HeFH). ∘ in adults and pediatric patients aged 7 years and older with homozygous familial hypercholesterolemia (HoFH). • As an adjunct to diet for the treatment of adults with: ∘ Primary dysbetalipoproteinemia. ∘ Hypertriglyceridemia. CRESTOR is an HMG Co‑A reductase inhibitor (statin) indicated: ( 1 ) • To reduce the risk of major adverse cardiovascular (CV) events (CV death, nonfatal myocardial infarction, nonfatal stroke, or an arterial revascularization procedure) in adults at increased risk for these events. • As an adjunct to diet and exercise to reduce low-density lipoprotein cholesterol (LDL-C): ∘ in adults with primary hypercholesterolemia. ∘ and slow the progression of atherosclerosis in adults. ∘ in adults and pediatric patients aged 8 years and older with heterozygous familial hypercholesterolemia (HeFH). ∘ in adults and pediatric patients aged 7 years and older with homozygous familial hypercholesterolemia (HoFH). • As an adjunct to diet for the treatment of adults with: ∘ Primary dysbetalipoproteinemia. ∘ Hypertriglyceridemia.
Mechanism: CRESTOR is an inhibitor of HMG‑CoA reductase, the rate-limiting enzyme that converts 3‑hydroxy‑3‑methylglutaryl coenzyme A to mevalonate, a precursor of cholesterol.
Therapeutic areas: Cardiovascular and metabolic
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- May 27, 2016 Supplement 33 · Efficacy OrphanLetterLabel
- Nov 20, 2015 Supplement 31 · Efficacy LetterLabel
- Feb 8, 2010 Supplement 16 · Efficacy ReviewLetterSummary Review
- Oct 15, 2009 Supplement 17 · Efficacy · priority review Pediatric Written RequestLabelLetter
- Nov 6, 2008 Supplement 13 · Efficacy LetterLabel
- Nov 8, 2007 Supplement 10 · Efficacy LabelReviewOther
- Aug 12, 2003 Original approval · Type 1 - New Molecular Entity NovelOrphanPediatric Written RequestPediatric Medical ReviewPediatric Clinical Pharmacology Review
4 products under this application
- CRESTOR · ROSUVASTATIN CALCIUM EQ 20MG BASE · TABLET, ORAL · Prescription · TE AB
- CRESTOR · ROSUVASTATIN CALCIUM EQ 5MG BASE · TABLET, ORAL · Prescription · TE AB
- CRESTOR · ROSUVASTATIN CALCIUM EQ 40MG BASE · TABLET, ORAL · Prescription · TE AB
- CRESTOR · ROSUVASTATIN CALCIUM EQ 10MG BASE · TABLET, ORAL · Prescription · TE AB
Clinical trials
Interventional ClinicalTrials.gov studies with "Rosuvastatin" as an intervention, any sponsor and status, largest first.
- Randomized Comparison of Morning Versus Bedtime Administration of Statins: A Cardiovascular Circadian Chronotherapy (C3) TrialPivotal-lookingNot yet recruiting
Tor Biering-SørensenAcademic, hospital or other
NCT06856772 · 42,000 participants (planned) · Start Feb 28, 2025 · Primary completion Mar 28, 2028
Drug: Statin in the evening (such as Simvastatin, Atorvastatin, Rosuvastatin, Pravastatin); Statin in the morning (such as Simvastatin, Atorvastatin, Rosuvastatin, Pravastatin) · For: Cardiovascular Diseases (CVD); Drug Effect; Atherosclerosis Cardiovascular Disease
Sites: Hellerup, Denmark
- ODYSSEY Outcomes: Evaluation of Cardiovascular Outcomes After an Acute Coronary Syndrome During Treatment With AlirocumabPivotal-lookingCompleted
SanofiSanofi (SNY)
NCT01663402 · 18,924 participants · Start Oct 2012 · Primary completion Jan 23, 2018
Drug: Alirocumab; Placebo and 1 more · For: Atherosclerotic Cardiovascular Disease
Sites: Birmingham, Alabama; Huntsville, Alabama; Mobile, Alabama · 1,388 sites in all
- JUPITER - Crestor 20mg Versus Placebo in Prevention of Cardiovascular (CV) EventsPivotal-lookingTerminated
AstraZenecaAstraZeneca (AZN)
NCT00239681 · 17,802 participants · Start Feb 2003 · Primary completion Sep 2008
Drug: Rosuvastatin · For: Elevated High-sensitivity C-Reactive Protein (hsCRP)
Sites: Birmingham, Alabama; Calera, Alabama; Columbiana, Alabama · 856 sites in all
- Heart Outcomes Prevention Evaluation-3Pivotal-lookingCompleted
Population Health Research InstituteAcademic, hospital or other
NCT00468923 · 12,705 participants · Start May 2007 · Primary completion Dec 2015
Drug: Candesartan/HCT; Rosuvastatin · For: Cardiovascular Disease; Stroke
Sites: Hamilton, Canada
- Primary Prevention of Major Adverse Cardiac Events (MACE) With Standard and Intensive Statin Treatment in Patients With Diabetes: Survival and Cardiovascular Event AssessmentsPivotal-lookingTerminated
Positive Trial GroupAcademic, hospital or other
NCT01173939 · 10,000 participants (planned) · Start Jul 2010 · Primary completion Jun 2014
Drug: Pravastatin; Rosuvastatin · For: Hypercholesterolemia; Type 2 Diabetes; Hypertension
Sites: Nagoya, Japan; Iyo Gun, Japan; Matsuyama, Japan · 317 sites in all
Fudan UniversityAcademic, hospital or other
NCT03418974 · 10,000 participants · Start Nov 1, 2017 · Primary completion Dec 31, 2021
Drug: Pitavastatin; Atorvastatin and 1 more · For: Dyslipidemias
Sites: Beijing, China; Shanghai, China
- Polypill and RiscOMeter to Prevent StrOke and CogniTive ImpairmEnt (PROMOTE)Pivotal-lookingRecruiting
Hospital Moinhos de VentoAcademic, hospital or other
NCT05155137 · 8,518 participants (planned) · Start Dec 20, 2021 · Primary completion Dec 14, 2029
Drug: Drug Capsule (Valsartan + Amlodipine + Rosuvastatin) · For: Stroke; Cognitive Decline
Sites: Porto Alegre, Brazil · 2 sites in all
- Polypills Approach for Multiple Cardiovascular Risk FactorsPivotal-lookingRecruiting
China Medical University, ChinaAcademic, hospital or other
NCT07679828 · 8,252 participants (planned) · Start Jul 11, 2026 · Primary completion Dec 31, 2029
Drug: Fixed-Dose Combination Strategy · For: Hypertension; Dyslipidemia; Diabetes
Sites: Zhengzhou, China; Chifeng, China; Tongliao, China · 15 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- fatigue12,643
- nausea10,873
- diarrhoea10,009
- drug ineffective9,957
- dyspnoea9,810
- off label use9,289
- myalgia9,259
- pain8,962
- headache8,466
- dizziness8,274
- arthralgia7,767
- asthenia7,654
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2004 | 2,921 |
| 2005 | 2,047 |
| 2006 | 3,055 |
| 2007 | 2,421 |
| 2008 | 3,898 |
| 2009 | 5,904 |
| 2010 | 7,391 |
| 2011 | 9,524 |
| 2012 | 11,040 |
| 2013 | 7,390 |
| 2014 | 8,106 |
| 2015 | 10,275 |
| 2016 | 10,288 |
| 2017 | 9,901 |
| 2018 | 11,123 |
| 2019 | 11,854 |
| 2020 | 11,540 |
| 2021 | 11,928 |
| 2022 | 12,119 |
| 2023 | 12,833 |
| 2024 | 13,919 |
| 2025 | 15,891 |
| 2026 | 12,523 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Crestor (Rosuvastatin Calcium)
2024 spending
$31.9M
Beneficiaries
13,827
54,565 claims
Per beneficiary
$2,309
$8.79 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $54,380,618 |
| 2021 | $48,218,264 |
| 2022 | $42,887,889 |
| 2023 | $38,872,959 |
| 2024 | $31,919,838 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein.
Ridker PM, Danielson E, Fonseca FA, et al. · N Engl J Med 2008 · Multicenter Study, Randomized Controlled Trial
- Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR* Trial).
Jones PH, Davidson MH, Stein EA, et al. · Am J Cardiol 2003 · Clinical Trial, Comparative Study
- Comparative Effects of Low-Dose Rosuvastatin, Placebo, and Dietary Supplements on Lipids and Inflammatory Biomarkers.
Laffin LJ, Bruemmer D, Garcia M, et al. · J Am Coll Cardiol 2023 · Clinical Trial, Phase II, Randomized Controlled Trial
- Comparative efficacy and safety among high-intensity statins. Systematic Review and Meta-Analysis.
Jaam M, Al-Naimi HN, Haddad MM, et al. · J Comp Eff Res 2023 · Meta-Analysis, Systematic Review
- Rosuvastatin versus atorvastatin treatment in adults with coronary artery disease: secondary analysis of the randomised LODESTAR trial.
Lee YJ, Hong SJ, Kang WC, et al. · BMJ 2023 · Multicenter Study, Randomized Controlled Trial
- Comparative Lipid-Lowering/Increasing Efficacy of 7 Statins in Patients with Dyslipidemia, Cardiovascular Diseases, or Diabetes Mellitus: Systematic Review and Network Meta-Analyses of 50 Randomized Controlled Trials.
Zhang X, Xing L, Jia X, et al. · Cardiovasc Ther 2020 · Network Meta-Analysis, Systematic Review
Sponsor: AstraZeneca
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.